Meeting
2021 ASCO Annual Meeting
A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study).
Authors
Tomomi Fujisawa
Department of Breast Oncology, Gunma Prefectural Cancer Center, Gunma, Japan
Tomomi Fujisawa , Tadahiko Shien , Hiroji Iwata , Hideo Shigematsu , Taro Shibata , Keita Sasaki , Yuko Takahashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
jRCTs031190129
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS601)
DOI
10.1200/JCO.2021.39.15_suppl.TPS601
Abstract #
TPS601
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
First Author: Veronique Debien
Poster
2021 ASCO Annual Meeting
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
First Author: Ciara Catherine Maria O'Sullivan
Poster
2019 ASCO Annual Meeting
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
First Author: Luca Gianni
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring